379 related articles for article (PubMed ID: 27287854)
1. Management of Pemphigus Vulgaris.
Cholera M; Chainani-Wu N
Adv Ther; 2016 Jun; 33(6):910-58. PubMed ID: 27287854
[TBL] [Abstract][Full Text] [Related]
2. Pemphigus vulgaris: approach to treatment.
Sinha AA; Hoffman MB; Janicke EC
Eur J Dermatol; 2015 Apr; 25(2):103-13. PubMed ID: 25547117
[TBL] [Abstract][Full Text] [Related]
3. [Pemphigus: a review].
Joly P; Sin C
Ann Dermatol Venereol; 2011 Mar; 138(3):182-200. PubMed ID: 21397148
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.
Doukaki S; Platamone A; Alaimo R; Bongiorno MR
J Dermatolog Treat; 2015 Feb; 26(1):67-72. PubMed ID: 24521072
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
Sami N; Qureshi A; Ruocco E; Ahmed AR
Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
[TBL] [Abstract][Full Text] [Related]
7. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
Engineer L; Bhol KC; Ahmed AR
J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
[TBL] [Abstract][Full Text] [Related]
8. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris.
McMillan R; Taylor J; Shephard M; Ahmed R; Carrozzo M; Setterfield J; Grando S; Mignogna M; Kuten-Shorrer M; Musbah T; Elia A; McGowan R; Kerr AR; Greenberg MS; Hodgson T; Sirois D
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Aug; 120(2):132-42.e61. PubMed ID: 25934414
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pemphigus vulgaris: current and emerging options.
Yeh SW; Sami N; Ahmed RA
Am J Clin Dermatol; 2005; 6(5):327-42. PubMed ID: 16252932
[TBL] [Abstract][Full Text] [Related]
10. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris.
Chams-Davatchi C; Esmaili N; Daneshpazhooh M; Valikhani M; Balighi K; Hallaji Z; Barzegari M; Akhyani M; Ghodsi SZ; Seirafi H; Nazemi MJ; Mortazavi H; Mirshams-Shahshahani M
J Am Acad Dermatol; 2007 Oct; 57(4):622-8. PubMed ID: 17583373
[TBL] [Abstract][Full Text] [Related]
12. Emerging treatment options for the management of pemphigus vulgaris.
Kridin K
Ther Clin Risk Manag; 2018; 14():757-778. PubMed ID: 29740210
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pemphigus vulgaris: part 1 - current therapies.
Yanovsky RL; McLeod M; Ahmed AR
Expert Rev Clin Immunol; 2019 Oct; 15(10):1047-1060. PubMed ID: 31566020
[No Abstract] [Full Text] [Related]
14. Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies.
Zhao W; Wang J; Zhu H; Pan M
Clin Rev Allergy Immunol; 2021 Dec; 61(3):351-362. PubMed ID: 34350539
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris.
Baskan EB; Yilmaz M; Tunali S; Saricaoglu H
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1432-4. PubMed ID: 19470052
[TBL] [Abstract][Full Text] [Related]
16. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?
Tavakolpour S
Int Immunopharmacol; 2017 Dec; 53():133-142. PubMed ID: 29107213
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris.
Koga H; Ishii N; Hamada T; Karashima T; Nakama T; Yasumoto S; Hashimoto T
Eur J Dermatol; 2010; 20(4):472-5. PubMed ID: 20406724
[TBL] [Abstract][Full Text] [Related]
18. The management of pemphigus vulgaris in a burn intensive care unit: a case report and treatment review.
Miletta N; Miller ME; Lam T; Chung KK; Hivnor C
J Burn Care Res; 2014; 35(5):e357-63. PubMed ID: 24572296
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent.
Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B
Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375
[TBL] [Abstract][Full Text] [Related]
20. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.
Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Luger TA
Arch Dermatol; 2006 Nov; 142(11):1447-54. PubMed ID: 17116835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
